3 hours ago
1
Erik S. Lesser/Getty Images News
Merck (NYSE:MRK) announced late-stage trial data on Thursday suggesting that its Capvaxive vaccine, indicated for adults to prevent invasive pneumococcal disease and pneumonia, is also effective in those aged 2–18 years.
Citing a 30-day post-vaccination analysis from its Phase 3
© FBT Company 2025. All rights are reserved
English (US) ·